RxDoctor Payments DataLook up a doctor →

Ali Melhem, MD

Psychiatry · Steubenville, OHNPI 1285788430

Payments from drug & device makers

$681,193in general payments, 2019–2025

Across 814 payments — averaging $836.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$509K
  • Neurocrine Biosciences, Inc.$106K
  • E.r. Squibb & Sons, L.L.C.$31K
  • Otsuka America Pharmaceutical, Inc.$24K
  • Alkermes, Inc.$9K
  • Novocure Inc.$878
  • plus $912 from 9 others

What the payments were for

  • Consulting fees$17,6333%
  • Speaking & faculty fees$562,99583%
  • Travel & lodging$84,98712%
  • Food & beverage$15,4412%
  • Education$1380%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$681,193 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in Ohio.

See all psychiatry providers in Ohio

Medicare billing

Part B allowed, 2024
$27,902
Medicare patients
37
Services billed
205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole23$72,115
VraylarCariprazine Hcl43$59,624
Invega SustennaPaliperidone Palmitate15$54,650
Paliperidone ErPaliperidone22$5,061
Oxcarbazepine41$3,420
Aripiprazole35$3,330
Divalproex Sodium ErDivalproex Sodium56$3,065
Quetiapine Fumarate197$2,459
Chlorpromazine Hcl14$1,778
Lamotrigine ErLamotrigine11$1,459
Buspirone Hcl83$1,125
Clozapine19$1,023
Prazosin Hcl40$843
Lamotrigine122$839
Clomipramine Hcl17$815

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$24,408$72,11523 claims
AbbVieVraylar$508,892$59,62443 claims
Johnson & JohnsonInvega Sustenna$78$54,65015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in Ohio.

Other psychiatry in Steubenville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →